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Abstract 
We demonstrated the pattern in presentation of primary intracranial tumors in a population-
based cohort of patients aged 0–24 years identified from the National Cancer Registry for 
England, using linked medical records from primary care and hospitals. We used 
generalized additive models to estimate temporal changes in presentation rates. Borderline 
and malignant tumors presented at a similar rate in primary care (6.4 and 6.6 consultations 
per 100 patients each month) and in hospital (3.4 and 3.6). Benign tumors presented earlier 
but less frequently (rate = 4.4 and rate ratio = 0.75, 95% CI = 0.60–0.93 in primary care; rate 
= 2.6 and rate ratio = 0.83, 95% CI = 0.77–0.89 in hospital). Many tumors began presenting 
shortly before their diagnosis, but less aggressive tumors were likely to present earlier in 
primary care. Earlier detection of less aggressive tumors in primary care may reduce the risk 
of complications and morbidity among survivors. 
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1. Introduction 
Primary intracranial tumors are not commonly seen by many clinicians (incidence rate = 34 
per million children per year). However, they account for 25% of childhood cancers and are 
responsible for considerable morbidity and mortality.1 Many brain tumors are not diagnosed 
early enough because of the variability of their presentation, which means children may only 
present with a few symptoms or signs from a very long list of possible clinical features. Many 
of these symptoms may be attributed to more common pediatric conditions, especially in the 
first few consultations, before the possibility of an intracranial tumor is considered.2-5 We 
therefore have recommended persistence or recurrence of symptoms, instead of emergence 
of confirmatory features that may not be present until a tumor has reached an advanced 
state, as a more useful trigger for further investigations.2, 6 
Delays in diagnosing an intracranial tumor result in patient distress and parental anxiety, and 
may lead to lengthy disputes with healthcare professionals. Parents’ reactions to the 
eventual diagnosis are often very negative, especially when earlier opportunities exist for 
which a diagnosis could have been made.7 Because of this, a delayed diagnosis could 
adversely affect trust and adaptation to subsequent treatment. 
Studies on symptoms and signs of intracranial tumors were often limited to describing cases 
of a single morphological type, or examining a hospital-based cohort with little information 
from primary care.8-14 We demonstrated variations in primary and secondary care 
presentation between different morphological types in a population-based cohort to identify 
opportunities for their earlier detection. 
2. Methods 
2.1. Patient cohort 
Patients aged 0–24 years when diagnosed with a primary intracranial tumor between 1989 
and 2006 in England were identified from the National Cancer Registry.15 Intracranial tumors 
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are those that originated in the supratentorial compartment, midline, cerebellum, brainstem, 
ventricular system, meninges, cranial nerves or other intracranial locations as coded to the 
9th or 10th revision of the International Classification of Diseases (ICD), and with a 
compatible morphology code from the diagnostic groups III, IX.b.2, IX.d.8 and X.a in the third 
edition of the International Classification of Childhood Cancer.16-18 
Tumors in the central nervous system are classified by their histological degree of 
malignancy as one of WHO grade I to IV.19, 20 This information is not routinely captured by 
the National Cancer Registry because the grade of a neoplasm outside the central nervous 
system represents its degree of differentiation, which is a different concept. Intracranial 
tumors are also classified as benign (the fifth digit of morphology code = /0), borderline (/1) 
or malignant (/3) by neuropathologists according to ICD for Oncology, promulgated by the 
World Health Organization and the International Agency for Research on Cancer.21-23 For 
central nervous system tumors, behavior and WHO grade are closely related: benign and 
borderline tumors generally have a low grade (WHO I or II) and malignant ones a high grade 
(WHO III or IV). For example: 
            Morphology     Grade Behavior 
Choroid plexus papilloma   9390/0  I 0 (benign) 
Atypical choroid plexus papilloma  9390/1  II 1 (borderline) 
Choroid plexus carcinoma   9390/3  III 3 (malignant) 
This mapping is not exact and depends on cell type. Instead of using data from deriving 
WHO grade of an intracranial tumor, we analyzed data on tumor characteristics as recorded 
by neuropathologists. 
We excluded registrations using the same criteria as for the production of National Statistics 
in England: records with invalid dates, unknown sex, unknown vital status, secondary or 
metastatic tumors, patients not resident in England and Wales or records that failed Office 
for National Statistics validity checks. 24 Synchronous (different tumors with identical 
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diagnosis date belonging to an individual) or multiple primary tumors (in the same location in 
an individual) were also excluded since those patients were likely to have a genetic 
syndrome (e.g. neurofibromatosis, tuberous sclerosis), and thus outside the scope of this 
study. 
We obtained linked primary care records from Clinical Practice Research Datalink (CPRD, 
formerly General Practice Research Database) for patients diagnosed during 1989–2006, 
and linked records of in-patient stays in National Health Service hospitals in England from 
Hospital Episode Statistics (HES) for patients diagnosed during 1997–2006. The data in 
CPRD cover 5–10% of the UK population but are representative in age, sex and ethnicity 
(compared with UK Census 2011), and the diagnoses on cancer contained within have been 
validated internally and externally.25, 26 
Linkage of hospital records to the National Cancer Registry was carried out by the Thames 
Cancer Registry and the Northern and Yorkshire Cancer Registry and Information Service, 
and linkage of primary care records was commissioned by CPRD.27, 28 
2.2. Presentation rates 
We analyzed each occurrence of presentation within the longitudinal history of healthcare 
use by calculating monthly presentation rates, from the total number of relevant primary care 
consultations and hospital admissions accrued among brain tumor patients divided by the 
total observation time for the cohort. 
A presentation was assumed to be relevant when one of the presenting features in a CPRD 
consultation record or the main reason for admission in a HES episode record was from one 
of the eight symptom groups, categorized after a manual search of the full list of diagnostic 
codes: headache; other features of raised intracranial pressure (e.g. nausea, vomiting); 
convulsions; visual disturbances (e.g. features of cranial nerves II, III, IV or VI dysfunction); 
focal neurological deficits; growth or endocrine disorders; behavioral or cognitive problems; 
and general or non-specific symptoms (e.g. delayed milestone, irritability). 
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We also classified each hospital episode as ‘non-emergency’ or ‘emergency’ based on the 
method of admission. Episodes were classed as ‘emergency’ when a patient was admitted 
via the emergency department, directly by the general practitioner (directly or after 
consulting the duty hospital doctor), urgently from an outpatient clinic, or by urgent transfer 
from another hospital. 
The total observation time for the cohort is the sum of each patient’s observation time. For 
calculating hospital presentation rates, the observation time began on the later of the date of 
birth or the start of HES data and ended with the earlier of the date of death or the end of 
HES data. For primary care presentation rates, observation time began on the date of 
registration with the primary care practice and ended with the earliest of the date of birth, 
transfer-out date (if a patient had switched to a practice outside CPRD coverage), or last 
collection date (when data were last submitted by the practice). Each person’s observation 
time was divided into monthly intervals before and after the date of diagnosis in the National 
Cancer Registry, which has an international standard definition.29, 30 
We estimated presentation rates and their confidence intervals for 0–1, 1–3, 3–6, 6–12 and 
over 12 months from the definitive diagnosis of an intracranial tumor in generalized linear 
models, with the number of consultations or in-patient episodes as the response and the 
logarithm of the length of observation time as the offset. We also illustrated changes in 
presentation rate graphically (in supplementary materials) to overcome the problem of 
dividing continuous time into these artificial intervals. Data on healthcare use after diagnosis 
have been included to reduce statistical uncertainty associated with estimating rates of 
presentation around diagnosis, when those were clinically most important, by placing them 
at the center of the longitudinal data. 
Because the monthly rates showed wide fluctuations, the underlying trend was delineated 
using generalized additive modelling with a locally weighted regression (LOESS) smoother.31 
LOESS is a computationally intensive procedure for smoothing serial observations by fitting 
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a low-degree polynomial in a contiguous subset of neighboring observations centered on the 
index presentation. Weights are assigned to each observation in the regression model such 
that their size are inversely related to the distance from the observation of interest – 
reflecting that more distant events carry less weight in influencing the index presentation. 
The predicted mean value of the index observation is estimated from this weighted 
regression modelling process, which is repeated for each observation until the predicted 
value of every observation has been estimated.32-34 
Generalized additive modelling was carried out using functions in the ‘gam’ package and in 
the statistical language R.35, 36 Computationally intensive calculations were carried out on the 
High Performance Computing cluster at the London School of Hygiene and Tropical 
Medicine. 
3. Results 
We identified 9,799 patients diagnosed with a primary intracranial tumor between 1989 and 
2006 (including 5,061 patients diagnosed since 1997) from the National Cancer Registry, 
after excluding 279 patients with ineligible records. We obtained 3,787 linked CPRD records 
of 181 patients during 1989–2006 and 60,351 linked HES records of 3,959 patients 
diagnosed during 1997–2006. Patients with linked records had similar age and sex to those 
without any linked records. Patients with fast-growing tumors (e.g. embryonal tumor, glioma 
or choroid plexus tumor) or those sited close to strategic or key structures (e.g. brainstem, 
cerebellum and around the ventricles) were more likely to have a link record in HES than in 
CPRD, which was expected from our clinical experience. Further details of the cohorts and 
their linkage characteristics have been described elsewhere.2 
3.1. Primary care consultations 
The overall pre-diagnosis presentation rate for benign intracranial tumors was 25% lower 
than for malignant tumors (rate = 4.4 per 100 patients each month, rate ratio = 0.75, 95% CI 
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= 0.60–0.93), and the presentation rate for borderline tumors was similar to that for 
malignant tumors (rate = 6.4, rate ratio = 0.88, 95% CI = 0.76–1.01) (Table 1). 
Much of the increase in the presentation frequency of malignant intracranial tumors occurred 
in the final six months before their eventual diagnosis (Table 2). The presentation rate of 
borderline tumors began to increase earlier at 6–12 months before diagnosis, and over 12 
months before diagnosis in benign tumors. The peak presentation rate was reached within 
one month of diagnosis: 65.4 per 100 patients each month (95% CI = 40.1–106.8) in benign 
tumors, which was less than half the magnitude of the rate for borderline (177.6, 146.4–
215.4) or malignant tumors (158.2, 134.8–185.7). 
Many gliomas, embryonal tumors, choroid plexus tumors, pineal gland tumors and a 
substantial proportion of germ cell tumors (Figure 1 and Figure S3, S4, S6, S7 and S10 in 
supplementary material) are of malignant behavior, but they had a lower overall pre-
diagnosis presentation rate than pilocytic astrocytomas (Figure 2), after adjusting for age 
and year of diagnosis (Table 1). 
3.2. Hospital presentations 
The overall pre-diagnosis presentation rate for borderline intracranial tumors was similar to 
malignant tumors (all admissions: rate ratio = 0.97, 95% CI = 0.92–1.03; for emergency 
admissions: rate ratio = 0.98, 95% CI = 0.91–1.06), and that for benign tumors was 17% 
lower than malignant tumors for all admissions (0.83, 0.77–0.89) and 42% lower for 
emergency admissions (0.58, 0.51–0.66) (Table 1). 
The temporal pattern in the rate of hospital presentations for benign, borderline and 
malignant intracranial tumors was very similar up to 1–3 months before their diagnosis 
(Table 3). The presentation rate rose to peak levels in benign (rate = 104.3 per 100 patients 
each month, 95% CI = 96.3–113.0) and borderline tumors (142.7, 134.9–151.1) in the final 
month before diagnosis, but that in malignant tumors continued to rise to an average of over 
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one visit per patient each month (151.8, 95% CI = 148.4–155.4) at 1–3 months after 
diagnosis (Table 3). 
Emergency hospital presentations increased with time but were uncommon up to one month 
before diagnosis (between 2.8 and 3.5 per 100 patients each month) (Table 4). A steep 
increase in the presentation frequency occurred in the final month before diagnosis, with the 
highest rate occurring in borderline (81.0 per 100 patients each month, 95% CI = 75.1–87.3) 
and malignant tumors (79.2, 75.9–82.8). 
Many primary intracranial tumors started to present in hospital only in the last 1–2 months 
before their definitive diagnosis despite their morphological heterogeneity. For example, the 
hospital presentation rate of embryonal tumors (Figure 3) and of tumors in the sellar region 
(Figure 4) began to increase from the baseline at a similar time in the natural course of 
events before diagnosis. The difference between those two tumors of very different behavior 
was in the intensity of overall hospital service use and of emergency presentation in the 
month when they were eventually diagnosed. This presentation pattern was unlike the one 
seen in primary care, in which very few consultations came from patients with embryonal 
tumors until 1–2 months before diagnosis, whereas consultations began earlier and were 
more frequent from patients with tumors in the sellar region (pituitary tumors, 
craniopharyngiomas). 
4. Discussion 
The underlying pattern of presentation of intracranial tumors was remarkably similar despite 
differences in their cell type and malignant potential: the frequency of presentation increased 
steadily with time in the pre-diagnosis period and rose steeply in the final few months to a 
peak at around diagnosis, before falling sharply after diagnosis. Although our primary 
interest was in the presentation pattern before diagnosis, we have also included events after 
diagnosis to demonstrate (instead of assuming) the frequency of healthcare use peaked at 
the time of diagnosis. The main differences in presentation pattern between tumor types 
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were the point at which presentations began to rise rapidly from the background rate of 
healthcare use, indicating the earliest time at which brain tumors could be detected, and the 
intensity of consultations or admissions around diagnosis. Our findings support the 
hypothesis that presentation of symptoms attributable to an underlying intracranial tumor 
occurs with increasing intensity as the tumor grows and invades surrounding tissues, and 
that increase in the frequency of primary care or hospital visits may in itself be a more useful 
trigger for in-depth investigations than the presence of some specific features (such as focal 
neurological signs).2, 37-39 
Patients had been presenting in primary care for some months before they began to present 
in hospitals, and this was recorded as an increase in presentation rate in secondary care 
that came after the increase in primary care. The steep increase in consultation rates in 
highly malignant tumors (embryonal tumors, gliomas and choroid plexus tumors) occurred 
closer to diagnosis than predominantly benign tumors (in the sellar region, meninges or 
nerve sheath) (Figure S3–S9 in supplementary material). This suggested opportunities exist 
in primary care for earlier diagnosis of benign or borderline brain tumors, ones that have the 
potential to cause significant morbidity and life-threatening complications if left undetected. 
The increase in frequency of hospital presentations began at a similar time in the natural 
history of intracranial tumors regardless of their morphology. The peak presentation rate was 
higher for malignant tumors such as astrocytomas, embryonal tumors, choroid plexus 
tumors, germ cell tumors and pineal gland tumors than for benign tumors (Figure S1, S3, 
S5–S10 in supplementary material). This implied patients with malignant tumors were 
admitted to hospital more frequently, presumably due to the occurrence of complications 
(e.g. raised intracranial pressure, hydrocephalus or intracranial hemorrhage) in patients who 
were not diagnosed in primary care. This finding is consistent with previous observations 
that rapidly growing tumors generally have some of the shortest time to diagnosis.2, 4, 10-12, 40-
42 
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4.1. Strengths and limitations 
The linkage of primary and secondary care records to the National Cancer Registry has 
enabled investigation of the pattern of healthcare use in patients with a rare disease, which 
would have been logistically prohibitive if patients had to be recruited as a conventional 
cohort.43-45 Although the proportion of patients with linked primary care records was small, 
our cohorts represented patients with demographics typically seen in primary care and with 
tumor characteristics consistent with our clinical experience because of the population 
coverage of CPRD.25 
Earlier studies on diagnostic delays in children were often carried out using a hospital-based 
cohort in a specialist center and frequently limited to a specific tumor type.4, 10, 11, 40 In this 
study, we examined every tumor morphology and behavior in two related population-based 
cohorts to highlight the similarities and differences in presentation pattern in both primary 
and secondary care. The pre-diagnosis period in which consultation frequency was above 
the background rate was much shorter in malignant brain tumors than in benign tumors, a 
phenomenon that was consistent with previous studies on highly aggressive tumors such as 
medulloblastomas.10, 11, 40 Rather than directly estimating a symptom interval in each patient 
to estimate diagnostic delay for the entire population, we have chosen to estimate the 
pattern of healthcare service use in the population to quantify delay. Our approach avoids 
the inherent inaccuracy associated with measuring individual symptom interval,46 which is 
commonly defined as the length of time between the date of diagnosis and “the first 
presentation” of a relevant set of symptoms.47 Although an internationally recognized 
standard exists for the definition of date of diagnosis in cancer research,29, 30 we are not 
aware of the a similar standard for defining “the first presentation”. The “first presentation” is 
often presumed to be the earliest consultation as recalled by patients or the earliest 
presentation deemed to be associated with an underlying tumor in a clinician’s opinion. This 
lack of a robust definition causes difficulty in ensuring reproducibility and comparability of 
results between studies and in examining trends in diagnostic delay. We have avoided this 
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problem by tracing each patient’s contact with healthcare service throughout their entire 
history using the same symptom list and algorithm, and examining the resulting pattern in 
the study population. 
For children with a suspected brain tumor in the UK, the pattern of referral for investigation 
from primary to secondary care is similar to that for adults. In other healthcare systems, such 
children are often first seen by primary pediatric physicians, who have direct access to 
comprehensive investigations, including neuroimaging, as well as rights to admit patients 
directly to secondary care. International differences in the pattern of referral for 
investigations could affect outcomes. International comparison of survival in patients with 
brain tumors of similar biological characteristics may provide useful insights into the 
relationship between different health systems and outcomes. 
4.2. Conclusion and implications 
Despite their histological heterogeneity, the presentation patterns of brain tumors in children 
and young adults are more similar than expected. Variations are associated with differences 
in their malignant potential and their presumed speed of growth. Benign brain tumors 
present earlier in primary care than malignant tumors, but the difference in time at which 
brain tumors become symptomatic is less pronounced in secondary care. Malignant tumors 
are much more likely to present as an emergency in secondary care than benign tumors. 
These observations mean fewer opportunities exist in primary care for an earlier diagnosis of 
highly malignant tumors until serious complications have developed. 
Efforts to promote early diagnosis of brain tumors in children and young adults should 
therefore emphasize recognizing the increase in frequency of consultations in primary care, 
instead of focusing on the presence of specific symptoms or signs.2 Many patients detected 
in primary care are likely to have a benign or borderline intracranial tumor, and long-term 
morbidity in this group could be reduced by minimizing the risk of irreversible neurological 
damage from insidious tumor growth or from prolonged raised intracranial pressure. 
13 
Acknowledgements 
We thank Children with Cancer UK for funding this work through the Jane Davidson and 
Paul O’Gorman Scholarship. We also thank colleagues at the Cancer Survival Group, 
London School of Hygiene and Tropical Medicine for their guidance on data management 
and statistical analysis. 
This work uses data provided by patients and collected by the National Health Service in the 
United Kingdom as part of their care and support. 
Author contributions 
TPCC searched the literature, designed the study, carried out data management and 
statistical analysis, interpreted the findings and drafted the manuscript. AS helped with 
literature search, study design and contributed to interpretation of findings. DW helped with 
literature search. MPC helped with literature search, secured data access, advised on study 
design, data analysis and interpretation of findings. All authors contributed to revision of the 
manuscript. 
TPCC and MPC have full access to all the data in the study and takes responsibility for the 
integrity of the data and the accuracy of the data analysis. 
Declaration of conflicting interest 
TPCC’s doctoral fellowship was funded by Children with Cancer UK. DW and TPCC were 
funded by The Brain Tumour Charity to evaluate the impact of raising awareness of brain 
tumor symptoms. DW receives funding from the Health Foundation and is a member of the 
Children with Cancer UK Scientific Advisory Panel. MPC and AS do not have any conflict of 
interest. 
14 
Funding 
This study was funded by Children with Cancer UK (EPNC0610). Children with Cancer UK 
does not have any involvement in study design; in data collection, analysis and interpretation 
of findings; in the writing of the report; and in the decision to submit the article for publication. 
Ethical approval 
This study was approved by the Research Ethics Committee at the London School of 
Hygiene and Tropical Medicine (reference 5566). Use of patient information was approved 
by the Patient Information Advisory Group (succeeded by the National Health Service Health 
Research Authority Confidentiality Advisory Group) under Section 60 of the Health and 
Social Care Act 2001 and Section 251 of the National Health Service Act 2006 in England 
and Wales (reference PIAG 1-05(c)/2007 and PIAG 3-06(f)/2008). 
  
15 
References 
1. Stiller C. Childhood Cancer in Britain: Incidence, survival, mortality. Oxford, UK: 
Oxford University Press, 2007. 
2. Chu TP, Shah A, Walker D, et al. Pattern of symptoms and signs of primary 
intracranial tumours in children and young adults: a record linkage study. Arch Dis Child 
2015; 100: 1115-1122. DOI: 10.1136/archdischild-2014-307578. 
3. Hamilton W and Kernick D. Clinical features of primary brain tumours: a case-control 
study using electronic primary care records. Br J Gen Pract 2007; 57: 695-699. 
4. Dang-Tan T and Franco EL. Diagnosis delays in childhood cancer: a review. Cancer 
2007; 110: 703-713. DOI: 10.1002/cncr.22849. 
5. Wilne S, Collier J, Kennedy C, et al. Presentation of childhood CNS tumours: a 
systematic review and meta-analysis. Lancet Oncol 2007; 8: 685-695. DOI: 10.1016/S1470-
2045(07)70207-3. 
6. Chu TP, Shah A, Walker D, et al. Where are the opportunities for an earlier diagnosis 
of primary intracranial tumours in children and young adults? Eur J Paediatr Neurol 2017; 
21: 388-395. DOI: 10.1016/j.ejpn.2016.10.010. 
7. Dixon-Woods M, Findlay M, Young B, et al. Parents' accounts of obtaining a 
diagnosis of childhood cancer. Lancet 2001; 357: 670-674. DOI: 10.1016/S0140-
6736(00)04130-1. 
8. Crawford JR, Santi MR, Vezina G, et al. CNS germ cell tumor (CNSGCT) of 
childhood: presentation and delayed diagnosis. Neurology 2007; 68: 1668-1673. DOI: 
10.1212/01.wnl.0000261908.36803.ac. 
9. Dobrovoljac M, Hengartner H, Boltshauser E, et al. Delay in the diagnosis of 
paediatric brain tumours. Eur J Pediatr 2002; 161: 663-667. DOI: 10.1007/s00431-002-1088-
4. 
16 
10. Halperin EC and Friedman HS. Is there a correlation between duration of presenting 
symptoms and stage of medulloblastoma at the time of diagnosis? Cancer 1996; 78: 874-
880. DOI: 10.1002/(SICI)1097-0142(19960815)78:4<874::AID-CNCR26>3.0.CO;2-R. 
11. Halperin EC, Watson DM and George SL. Duration of symptoms prior to diagnosis is 
related inversely to presenting disease stage in children with medulloblastoma. Cancer 
2001; 91: 1444-1450. 
12. Kukal K, Dobrovoljac M, Boltshauser E, et al. Does diagnostic delay result in 
decreased survival in paediatric brain tumours? Eur J Pediatr 2009; 168: 303-310. DOI: 
10.1007/s00431-008-0755-5. 
13. Mauffrey C. Paediatric brainstem gliomas: prognostic factors and management. J 
Clin Neurosci 2006; 13: 431-437. DOI: 10.1016/j.jocn.2005.05.015. 
14. Reulecke BC, Erker CG, Fiedler BJ, et al. Brain tumors in children: initial symptoms 
and their influence on the time span between symptom onset and diagnosis. J Child Neurol 
2008; 23: 178-183. DOI: 10.1177/0883073807308692. 
15. Office for National Statistics. Cancer statistics registrations: Registrations of cancer 
diagnosed in 2006, England. Newport, UK: Office for National Statistics, 2008. 
16. Steliarova-Foucher E, Stiller C, Lacour B, et al. International Classification of 
Childhood Cancer, third edition. Cancer 2005; 103: 1457-1467. DOI: 10.1002/cncr.20910. 
17. World Health Organization. Manual of the international statistical classification of 
diseases, injuries, and causes of death. Geneva, Switzerland: World Health Organization, 
1977. 
18. World Health Organization. International statistical classification of diseases and 
related health problems. Geneva, Switzerland: World Health Organization, 1992. 
19. Kleihues P, Louis DN, Scheithauer BW, et al. The WHO classification of tumors of 
the nervous system. J Neuropathol Exp Neurol 2002; 61: 215-225; discussion 226-219. 
2002/03/16. DOI: 10.1093/jnen/61.3.215. 
17 
20. Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of 
the central nervous system. Acta Neuropathol 2007; 114: 97-109. DOI: 10.1007/s00401-007-
0243-4. 
21. Fritz AG, Percy CL, Jack A, et al. International Classification of Diseases for 
Oncology. 3rd ed. Geneva, Switzerland: World Health Organization, 2000. Available from 
http://codes.iarc.fr (accessed 3 Jan 2018). 
22. Fritz AG, Percy CL, Jack A, et al. International Classification of Diseases for 
Oncology. 1st revision of 3rd ed. Geneva, Switzerland: World Health Organization, 2013. 
Available from http://codes.iarc.fr (accessed 3 Jan 2018). 
23. Louis D, Ohgaki H, Wiestler O, et al. WHO Classification of Tumours of the Central 
Nervous System. 4th ed. Lyon, France: International Agency for Research on Cancer, 2007. 
24. Coleman MP, Babb P, Damiecki P, et al. Cancer survival trends in England and 
Wales, 1971-1995: deprivation and NHS region. London, UK: The Stationery Office, 1999. 
25. Herrett E, Gallagher AM, Bhaskaran K, et al. Data Resource Profile: Clinical Practice 
Research Datalink (CPRD). Int J Epidemiol 2015; 44: 827-836. DOI: 10.1093/ije/dyv098. 
26. Herrett E, Thomas SL, Schoonen WM, et al. Validation and validity of diagnoses in 
the General Practice Research Database: a systematic review. Br J Clin Pharmacol 2010; 
69: 4-14. DOI: 10.1111/j.1365-2125.2009.03537.x. 
27. Hanchett N. ONS to HES Linkage Release 1: Core Documentation. London, UK: 
Thames Cancer Registry, King's College London, 2008. 
28. Thames Cancer Registry. National Cancer Data Repository - 1990 to 2008: Matching 
Registry Records to Hospital Episodes Version 1.2. London, UK: Thames Cancer Registry, 
King's College London, 2011. 
29. International Agency for Research on Cancer and International Association of Cancer 
Registries. Cancer Registration: Principles and Methods. Lyon, France: International Agency 
for Research on Cancer, 1991. 
30. United Kingdom Association of Cancer Registries. Po/99/03 Definition of Diagnosis 
Date. United Kingdom Association of Cancer Registries, 2011. 
18 
31. Ansell P, Johnston T, Simpson J, et al. Brain tumor signs and symptoms: analysis of 
primary health care records from the UKCCS. Pediatrics 2010; 125: 112-119. DOI: 
10.1542/peds.2009-0254. 
32. Chambers J and Hastie T. Statistical Models in S. London, UK: Chapman & Hall, 
1993. 
33. Cleveland WS. Robust Locally Weighted Regression and Smoothing Scatterplots. 
Journal of the American Statistical Association 1979; 74: 829-836. DOI: 10.2307/2286407. 
34. Cleveland WS and Devlin SJ. Locally Weighted Regression - an Approach to 
Regression-Analysis by Local Fitting. Journal of the American Statistical Association 1988; 
83: 596-610. DOI: 10.2307/2289282. 
35. Hastie T. gam: Generalized Additive Models, http://CRAN.R-
project.org/package=gam (2011). 
36. R Core Team. R: A Language and Environment for Statistical Computing, 
http://www.R-project.org/ (2011). 
37. Dommett RM, Redaniel MT, Stevens MC, et al. Features of childhood cancer in 
primary care: a population-based nested case-control study. Br J Cancer 2012; 106: 982-
987. DOI: 10.1038/bjc.2011.600. 
38. Dommett RM, Redaniel MT, Stevens MC, et al. Features of cancer in teenagers and 
young adults in primary care: a population-based nested case-control study. Br J Cancer 
2013; 108: 2329-2333. DOI: 10.1038/bjc.2013.191. 
39. Hamilton W, Hajioff S, Graham J, et al. Suspected cancer (part 1--children and young 
adults): visual overview of updated NICE guidance. BMJ 2015; 350: h3036. DOI: 
10.1136/bmj.h3036. 
40. Brasme JF, Chalumeau M, Doz F, et al. Interval between onset of symptoms and 
diagnosis of medulloblastoma in children: distribution and determinants in a population-
based study. Eur J Pediatr 2012; 171: 25-32. DOI: 10.1007/s00431-011-1480-z. 
19 
41. Brasme JF, Grill J, Gaspar N, et al. Evidence of increasing mortality with longer time 
to diagnosis of cancer: is there a paediatric exception? Eur J Cancer 2014; 50: 864-866. 
DOI: 10.1016/j.ejca.2013.11.036. 
42. Mehta V, Chapman A, McNeely PD, et al. Latency between symptom onset and 
diagnosis of pediatric brain tumors: an Eastern Canadian geographic study. Neurosurgery 
2002; 51: 365-372; discussion 372-373. 
43. Fellegi IP and Sunter AB. A Theory for Record Linkage. Journal of the American 
Statistical Association 1969; 64: 1183-1210. DOI: 10.1080/01621459.1969.10501049. 
44. Gill L. Methods for Automatic Record Matching and Linkage and their Use in National 
Statistics. Norwich, UK: Her Majesty's Stationery Office, 2001. 
45. Statistics New Zealand. Data Integration Manual. Wellington, New Zealand: Statistics 
New Zealand, 2006. 
46. Launay E, Morfouace M, Deneux-Tharaux C, et al. Quality of reporting of studies 
evaluating time to diagnosis: a systematic review in paediatrics. Arch Dis Child 2014; 99: 
244-250. DOI: 10.1136/archdischild-2013-304778. 
47. Weller D, Vedsted P, Rubin G, et al. The Aarhus statement: improving design and 
reporting of studies on early cancer diagnosis. Br J Cancer 2012; 106: 1262-1267. DOI: 
10.1038/bjc.2012.68. 
  
20 
Figures and Tables 
Figure 1 Pattern of primary care presentations in children and young adults with an 
embryonal tumor before and after diagnosis (time = 0): England, 1989–2006. 
Change in monthly presentation rates (gray dots) after LOESS smoothing (solid line). 
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Figure 2 Pattern of primary care presentations in children and young adults with a pilocytic 
astrocytoma before and after diagnosis (time = 0): England, 1989–2006. 
Change in monthly presentation rates (gray dots) after LOESS smoothing (solid line). 
  
050
100
150
200
250
Pilocytic astrocytoma
Time from diagnosis (months)
Co
ns
ul
ta
tio
n 
ra
te
 (p
er 
10
0 p
ers
on
−m
on
ths
)
36 24 12 0 12 24 36
Before diagnosis After diagnosis
22 
Figure 3 Pattern of hospital presentations in children and young adults with an embryonal 
tumor before and after diagnosis (time = 0): England, 1997–2006. 
Change in monthly rates of all presentations (black dots) after LOESS smoothing (black 
line), and of emergency presentations (gray dots) after LOESS smoothing (gray line). 
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Figure 4 Pattern of hospital presentations in children and young adults with a tumor in the 
sellar region before and after diagnosis (time = 0): England, 1997–2006. 
Change in monthly rates of all presentations (black dots) after LOESS smoothing (black 
line), and of emergency presentations (gray dots) after LOESS smoothing (gray line). 
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Supplementary material 
● Figures represent temporal change in presentation rate in children and young adults 
(age at diagnosis = 0–24 years) with intracranial tumor before and after diagnosis 
(time = 0 at brain tumor diagnosis) in England. 
● Left: primary care presentations (1989–2006) 
○ grey dots: observed rates 
○ black line: predicted rates after locally weighted regression (LOESS) 
smoothing 
● Right: hospital presentations (1997–2006) 
○ black dots: observed rates of all admissions 
○ red dots: observed rates of emergency admissions only 
○ black line: predicted rates of all admissions after LOESS smoothing 
○ red line: predicted rates of emergency admissions after LOESS smoothing 
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